Show simple item record

Síndrome hemolítico urémico atípico en tratamiento con eculizumab. Casos Clínicos

dc.contributoren-US
dc.contributores-ES
dc.creatorTagle, Rodrigo; Hospital Clínico Universidad Católica – Red de Salud UC Christus, Departamento de Nefrología, Pontificia Universidad Católica de Chile. Facultad de Medicina, Pontificia Universidad Católica de Chile.
dc.creatorRivera, Gustavo; Facultad de Medicina, Pontificia Universidad Católica de Chile.
dc.creatorWalbaum, Benjamín; Facultad de Medicina, Pontificia Universidad Católica de Chile.
dc.creatorSepúlveda, Rodrigo A; Hospital Clínico Universidad Católica – Red de Salud UC Christus, Departamento de Nefrología, Pontificia Universidad Católica de Chile. Facultad de Medicina, Pontificia Universidad Católica de Chile.
dc.date2018-03-14
dc.date.accessioned2019-11-11T18:27:42Z
dc.date.available2019-11-11T18:27:42Z
dc.identifierhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6487
dc.identifier.urihttps://revistaschilenas.uchile.cl/handle/2250/111267
dc.descriptionHemolytic uremic syndrome (HUS) is a type of thrombotic microangiopathy where organic damage predominates in the kidney. Atypical HUS (aHUS) is a rare disease that affects young adults and causes terminal chronic renal failure ending in dialysis, in most cases. It also recurs after kidney transplantation. aHUS is associated with genetic defects of the alternative complement pathway or its activation by other factors such as drugs, autoimmune diseases, infections, malignant hypertension and ischemia-reperfusion. We report two women aged 17 and 25 years old with catastrophic aHUS. In both cases, complement amplifying factors (drugs and infections) were added and acted on a genetic vulnerability to precipitate complement activation and produce aHUS. Both patients developed terminal renal failure and had to undergo hemodialysis. Fortunately, after a broad etiological study, it was possible to make the diagnosis of aHUS and start treatment with Eculizumab, a monoclonal antibody that changed the natural history of aHUS. It inhibits complement activity controlling microangiopathy and preventing the development of end-stage renal disease. It also improves the success rate in kidney transplantation. In the case of our patients, both discontinued dialysis after chronic treatment with Eculizumab.en-US
dc.descriptionHemolytic uremic syndrome (HUS) is a type of thrombotic microangiopathy where organic damage predominates in the kidney. Atypical HUS (aHUS) is a rare disease that affects young adults and causes terminal chronic renal failure ending in dialysis, in most cases. It also recurs after kidney transplantation. aHUS is associated with genetic defects of the alternative complement pathway or its activation by other factors such as drugs, autoimmune diseases, infections, malignant hypertension and ischemia-reperfusion. We report two women aged 17 and 25 years old with catastrophic aHUS. In both cases, complement amplifying factors (drugs and infections) were added and acted on a genetic vulnerability to precipitate complement activation and produce aHUS. Both patients developed terminal renal failure and had to undergo hemodialysis. Fortunately, after a broad etiological study, it was possible to make the diagnosis of aHUS and start treatment with Eculizumab, a monoclonal antibody that changed the natural history of aHUS. It inhibits complement activity controlling microangiopathy and preventing the development of end-stage renal disease. It also improves the success rate in kidney transplantation. In the case of our patients, both discontinued dialysis after chronic treatment with Eculizumab.es-ES
dc.formatapplication/pdf
dc.languagespa
dc.publisherRevista Médica de Chilees-ES
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/6487/3777
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32874
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32875
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32876
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32877
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32878
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32879
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32880
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/32953
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/33101
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/33881
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/33882
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/33883
dc.relationhttp://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/downloadSuppFile/6487/34096
dc.sourceRevista Médica de Chile; Vol. 146, núm. 2 (2018): FEBRERO 2018es-ES
dc.source0034-9887
dc.subjectAntibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathiesen-US
dc.subjectAntibodies, Monoclonal, Humanized; Atypical Hemolytic Uremic Syndrome; Thrombotic Microangiopathieses-ES
dc.titleATYPICAL HEMOLYTIC UREMIC SYNDROME. REPORT OF TWO CASES TREATED WITH ECULIZUMABen-US
dc.titleSíndrome hemolítico urémico atípico en tratamiento con eculizumab. Casos Clínicoses-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typees-ES


This item appears in the following Collection(s)

Show simple item record